URGN

Urogen Pharma Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 3/10
  • Value↓ 0/10
Urogen Pharma sales and earnings growth
URGN Growth
Neutral
  • Revenue Y/Y↑ 52.92%
  • EPS Y/Y↑ 10.46%
  • FCF Y/Y↓ -54.60%
Urogen Pharma gross and profit margin trends
URGN Profitability
Neutral
  • Gross margin ↑ 89.90%
  • EPS margin↓ -94.80%
  • ROIC 5Y↓ -62.85%
Urogen Pharma net debt vs free cash flow
URGN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.5
  • Interest coverage↓ -7.9

Urogen Pharma stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks